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Change from three times a week on-line hemodiafiltration to The frequency of hemodialysis was established as thrice
short daily on-line hemodiafiltration. weekly in the 1960s and it has been mainly accepted
Background. Daily dialysis has shown excellent clinical re- and maintained for logistical, pragmatic, and economic
sults because a higher frequency of dialysis is more physiologic. reasons. However, there is a growing interest in the useOn-line hemodiafiltration (OL-HDF) is a HDF technique that
of more frequent dialysis schedules since long-term expe-combines diffusion with high convection in which the dialysis
riences using higher frequencies have shown good resultsfluid itself is used as a reinfusion solution. The aim of this study
[1–5]. The first experiences with daily dialysis were re-was to demonstrate the beneficial effect of the more effective
dialysis schedule (daily dialysis) with the dialysis modality that ported in 1967 [6] and two predominant treatment sched-
offers the highest uremic toxin removal (on-line HDF). ules have been established. Short daily dialysis [1, 2, 4]
Methods. Eight patients, six males and two females, on stan- has been used for more than 20 years and slow nightly
dard 4 to 5 hours three times a week OL-HDF (S-OL-HDF) dialysis [5, 7, 8] has been used since 1995. Although therewere switched to daily OL-HDF (D-OL-HDF) 2 to 21⁄2 hours are only a few studies and the number of patients issix times per week. Dialysis parameters were identical during
limited, they show excellent clinical results because aboth periods and only frequency and dialysis time of each
higher frequency of dialysis is more physiologic and itsession were changed. Tolerance, uremic toxin removal, urea
kinetics, biochemical and anemia profiles, blood pressure, and decreases fluctuations in fluid volume, solutes, and elec-
left ventricular hypertrophy were evaluated. trolytes. Improvements in comfort during and between
Results. D-OL-HDF was well accepted and tolerated. The dialysis sessions, clinical and biochemical parameters,
disappearance of postdialysis fatigue was rapidly reported by anemia correction, hypertension control, nutrition status,
patients. Patients mantained the same [time average concentra- and quality of life have been reported.tion (TAC) and weekly single-pool Kt/V (spKt/V)] throughout
On-line hemodiafiltration (OL-HDF) could offer an op-the study. However, equivalent renal urea clearance (EKR),
timal form of extracorporeal treatment for dialysis patients.standard Kt/V and weekly urea reduction ratio (URR) were
This technique, which combines diffusion with high con-increased during D-OL-HDF. Weekly urea, creatinine, osteocal-
cin,2-microglobulin, myoglobin, and prolactin reduction ratios vection [infusion flux (Qi) 50 to 200 mL/minute or 3–12
were improved with D-OL-HDF. There was a significant de- L/hour], provides the highest clearances per unit of surface
crease in predialysis plasma levels of urea, creatinine, acid uric, area for small, medium, and large-sized molecules. The
2-microglobulin and homocysteine over 6 months. Phosphate same dialysis fluid, free of toxins and pyrogens, is used as
binders were reduced and antihypertensive drugs were stopped. substitution solution. It is a safe, well-tolerated technique,A 30% regression of left ventricular mass was observed.
and good clinical results have been observed [9–11].Conclusion. The change from S-OL-HDF to D-OL-HDF
In this study, we sought to combine the more physio-was well tolerated. Disappearance of postdialysis fatigue, bet-
logic and effective dialysis schedule (daily dialysis) withter dialysis adequacy, a higher removal of middle and large
molecules, a reduction of phosphate binders, improvement of the dialysis modality that offers higher solute and uremic
status nutritional, and an important reduction of cardiovascular toxine removal (OL-HDF). The aim of this study was to
risk factors were observed. change patients from standard 4 to 5 hours three times a
week OL-HDF to 2 to 21⁄2 hours six times a week OL-HDF,
and evaluate the impact of higher frequency therapy on solute
Key words: dialysis adequacy, daily hemodialysis, nutrition, on-line removal capacity and on biochemical and clinical outcomes.hemodiafiltration, solute removal.
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with a mean age of 65.9  14 years (range, 41 to 80 ng/mL in our laboratory. Serum 2-microglobulin was
measured using the Quantex 2-microglobulin commer-years), stable on hemodialysis over a period of 68.4 
43 months and on standard 4 to 5 hours three times a cial immunoturbidimetry, which has a normal range of
1.1 to 2.4 mg/L. Myoglobin concentrations were mea-week OL-HDF (S-OL-HDF) during the last 36.3  21
months (range, 8 to 68 months) were switched to daily sured by a commercial immunoenzymatic “sandwich”
assay (Access; Beckman, Fullerton, CA, USA), whichOL-HDF (D-OL-HDF) 2 to 21⁄2 hours six times per week.
The underlying renal diseases were chronic glomerulo- has a normal range of 0 to 70 ng/mL. Prolactin concentra-
tions were measured by a commercial immunometricnephritis in two patients, nephroangiosclerosis in two
patients, polycystic kidney disease in one patient, chronic assay, Immulite 2000 DPC, which has a normal range of
3 to 30 ng/mL. The pre- to posttreatment reduction ratiostubulointerstitial nephritis in one patient, diabetic ne-
phropathy in one patient, and undiagnosed nephropathy in plasma for osteocalcin, 2-microglobulin, myoglobin,
and prolactin were determined after correcting postdial-in one patient. All patients signed consent forms ap-
proved by the Hospital Research Committee. ysis concentrations using the method of Bergstro¨m and
Wehle [17].The S-OL-HDF parameters were as follows: dialysis
buffer with bicarbonate, 1.8 m2 high-flux polysulfone filter The second part of study was designed to evaluate
biochemical and clinical outcomes. The last 6 months on(HF80, Fresenius, Bad Homburg, Germany), blood flow
(Qb) 445  54 mL/min (range, 350 to 560 mL/min), S-OL-HDF, during which conditions of treatment were
not varied, were taken as the baseline period, beforedialysate flow (Qd) 800 mL/min minus the infusion flow
(Qi), which ranged from 80 to 150 mL/min and a Fresen- switching the patients to D-OL-HDF. Treatment was
carried out over 6 months. Each month at mid-week,ius 4008 dialysis monitor. Reinfusion was always per-
formed in a postdilutional mode. On D-OL-HDF, these predialysis plasma analyses for hemoglobin, hematocrit,
ferritin, transferrin saturation, fibrinogen, urea, creati-parameters were the same and only the frequency and
dialysis duration of each session were changed. All pa- nine, sodium, potassium, uric acid, bicarbonate, calcium,
phosphorus, intact parathyroid hormone (iPTH), serumtients had native arteriovenous fistulas. The dialysers
were not reused. Residual renal function was negligible protein, albumin, prealbumin, transferrin, total choles-
terol, high-density lipoprotein (HDL) cholesterol, low-in all patients. Before the study period, six patients used
15-gauge needles and two used 14-gauge needles. All density lipoprotein (LDL) cholesterol, triglycerides, 2-
microglobulin, myoglobin, and C-reactive protein werepatients used 15-gauge needles while on D-OL-HDF
(Qb was limited to 500 mL/min). carried out, as well as a quarterly analysis of homocys-
teine. Homocysteine was determined by the IMx methodThe following urea kinetic parameters were calcu-
lated: single-pool second-generation Daugirdas Kt/V (IMX System; Abbott, Wiesbaden, Germany), using
fluorescence polarization immunoassay technology.(spKt/V) [12], equilibrated Kt/V (eKt/V) [13], urea re-
duction ratio (URR), time average concentration (TAC), At baseline and each month, each patient completed
a fatigue index questionnaire concerning the intensityand normalized protein catabolic rate (nPCR). More-
over, different yardsticks proposed to measure the dial- and duration of frequency of postdialysis fatigue [18].
Fatigue intensity was scored as follows: 0, none; 1, mildysis dose delivered by the different dialysis regimens
have also been included: weekly spKt/V, weekly eKt/V, (noticeable but without effect); 2, moderate (felt slug-
gish); 3, severe (required rest); or 4, overwhelming (slept).the equivalent renal urea clearance (EKR) introduced
by Casino and Lopez [14], the standard Kt/V described Fatigue duration was scored as follows: 0, none; 1, mild
(one to 4 hours); 2, moderate (6 to 12 hours); 3, severeby Gotch [15] and, finally, we calculated the weekly URR
and the time average deviation (TAD) introduced by (12 to 24 hours); or 4, overwhelming (more than 24 hours).
Predialysis blood pressure was measured immediatelyLopot and Va`lek [16].
To evaluate removal capacity between both treat- before treatment with an automatic blood pressure mon-
itor (BPM). Left ventricular hypertrophy (LVH) wasments modes, “in vivo” removal of a wide spectrum of
solutes was studied. Pre- and postdialysis concentrations evaluated by magnetic resonance imaging (MRI). Mea-
surements included left ventricular internal diameter atof urea (60 D), creatinine (113 D), osteocalcin (5800 D),
2-microglobulin (11,800 D), myoglobin (17,000 D), and end-diastole (LVIDD) and left ventricular internal diam-
eter at end-systole (LVISD), interventricular septal thick-prolactin (23,000 D) were measured. Pretreatment blood
samples were drawn immediately after access needle in- ness (IVS), anterior wall thickness at end-diastole (AWT),
posterior wall thickness at end-diastole (PWT), lateralsertion. Posttreatment samples were drawn from the ar-
terial blood line 60 seconds after decreasing the blood wall thickness at end-diastole (LWT), inferior wall thick-
ness at end-diastole (IWT), left atrium dimension (LA)flow rate to 50 mL/min. Osteocalcin concentrations were
measured by a commercial immunometric assay, Immu- and aortic root dimension (AO). Left ventricular wall
mass (LVM) was calculated by outlining endo- and epi-lite (DPC Diagnostics, Los Angeles, CA, USA) osteocal-
cin. The normal range of osteocalcin values is 3.1 to 13.7 cardial contours on a stack of image sections of a specific
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Table 1. Change from three times a week on-line hemodiafiltration
(OL-HDF) to short daily on-line hemodiafiltration (D-OL-HDF):
Comparison of urea kinetics during the two study periods
Baseline Month 3 Month 6
spKt/V 2.300.20 1.130.15b 1.110.11b
eKt/V 1.960.17 0.900.12b 0.880.08b
URR % 84.32.5 64.25.3b 63.34.2b
Weekly spKt/V 6.900.59 6.780.91 6.670.64
Weekly eKt/V 5.880.52 5.390.75a 5.300.50a
EKR mL/min 19.20.5 24.22.6b 23.81.9b
stdKt/V 2.620.1 3.870.3b 3.860.2b
Weekly URR % 2537.5 38532b 38025b
TACBUN mg/dL 27.37.1 26.78.6 27.76.1
TADBUN mg/dL 9.692.3 6.242.1b 6.261.3b
Abbreviations are: URR, urea reduction ratio; spKt/V, single-pool Kt/V; eKt/V,
equilibrated Kt/V; stdKt/V, standard Kt/V; TAC, time average concentration;
TAD, time average deviation; ERK, equivalent renal urea clearance.
aP 0.05; bP 0.01 with respect to baseline value (ANOVA repeated measures)
Fig. 1. Percentage variation of different dialysis dose evaluations with
change from three times a week on-line hemodiafiltration (OL-HDF)
to short daily on-line hemodialfilitration (D-OL-HDF). Abbreviations
are: spKt/V, single-pool Kt/V; eKt/V, equilibrated Kt/V; ERK, equivalent
renal urea clearance; stdKt/V, standard Kt/V; URR, urea reduction ratio.time frame encompassing the ventricle, using Simpson’s
rule algorithm [19]. LVM index (LVMI) was calculated
by dividing LVM by body surface area. Left ventricular
end-diastolic volume (LVEDV), end-systolic volume
4 weeks, the patients reported a rapid improvement in(LVESV), and ejection fraction (EF) were also calcu-
the following symptoms: headaches in three patients,lated. All studies were performed and analyzed by the
sleep disorders in three patients, sexual disorders in twosame experienced cardiologist, who was blinded to the
patients, thoracic pain in one patient, increased appetitepatients’ data. Studies were performed on a mid-week
in five patients, and decreased thirst in two patients.nondialysis day in S-OL-HDF and on a mid-week day
The most significant benefit was the disappearance ofbefore dialysis in D-OL-HDF. Specific criteria were used
postdialysis fatigue. Fatigue intensity scores diminishedto determine the presence of LVH (men, LVM 158 g
from 1.88  1.2 in S-OL-HDF to 0.38  0.7 in S-OL-or LVMI 83 g/m2; women, LVM 123 g or LVMI
HDF (P  0.01), and fatigue duration scores decreased73 g/m2) [19].
from 1.75  1.4 in S-OL-HDF to 0.25  0.5 in S-OL-The results were expressed as the arithmetic mean 
HDF (P  0.01).standard deviation. Each patient served as his/her own
control. The Student t test (paired data) and analysis of Urea kinetics
variance (ANOVA) test (repetitive data) were used in
Throughout the study, patients mantained the samethe analysis of differences in quantitative variables. A
TAC, weekly spKt/V, and weekly eKt/V (Table 1). How-value of P  0.05 was considered statistically significant.
ever, EKR, standard Kt/V, and weekly URR were sig-
nificantly increased in D-OL-HDF. The percentage vari-
RESULTS ation of D-OL-HDF dialysis dose, measured by different
methods, is shown in Figure 1. The outcome of pre- andThe duration per dialysis session changed from 274 
postdialysis blood urea nitrogen (BUN), TACBUN, and25 minutes (range, 240 to 300 minutes) in S-OL-HDF
TADBUN is shown in Figure 2.to 133 12 minutes (range, 120 to 150 minutes) in D-OL-
HDF (P  0.01) but weekly dialysis time was similar,
Solute removal822 minutes versus 798 minutes (NS), respectively. Qb
Mean session values for urea, creatinine, osteocalcin,was 445  59 mL/min in S-OL-HDF versus 438  38
2-microglobulin, myoglobin, and prolactin reduction ra-mL/min in D-OL-HDF (NS). Mean session value for
tios were lower on D-OL-HDF; however, the weeklyreinfusion volume in S-OL-HDF was 30.7  6 L and
reduction ratios were significantly increased on D-OL-14.6 2 L in D-OL-HDF (P 0.01), and weekly reinfu-
HDF (Table 2). Figure 3 shows the weekly percentagesion volume was 95.8  21 L and 88.1  9 L (NS),
increase in the efficacy of D-OL-HDF over a broad spec-respectively.
trum of solutes in comparison with S-OL-HDF.Daily OL-HDF was well accepted and tolerated by
There was a significant decrease in predialysis levelsall patients. No local infections, thromboses, or bleeding
of urea, creatinine, uric acid (Table 3), and large mole-of the vascular access occurred. The number of nausea,
cules (2-microglobulin and myoglobin) over 6 monthsdizziness, cramps, and hypotensive episodes did not
change between the two treatment schedules. In the first (Fig. 4). The biochemical outcomes for predialysis so-
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Fig. 2. Evolution of pre and postdialysis blood urea nitrogen (BUN),
time average concentration (TAC)BUN and time average deviation Fig. 3. Increase in the weekly percentage removal of a broad spectrum(TAD)BUN switching from three times a week on-line hemodiafiltration of solutes with short daily on-line hemodiafiltration (D-OL-HDF) in(OL-HDF) to short daily on-line hemodiafiltration (D-OL-HDF). comparison with three times a week on-line hemodiafiltration (OL-
HDF). Abbreviations are: Crea, creatinine; Osteo, osteopontin; 2-m,
microglobulin; Myo, myoglobin; PRL, prolactin.
Table 2. Comparison of urea, creatinine, osteocalcin, 2-
microglobulin, myoglobin, and prolactin reduction ratios between
three times a week standard on-line hemodiafiltration (S-OL-HDF) dose was reduced from 24 IU/day at baseline to 12 IU/and short daily on-line hemodiafiltration (D-OL-HDF)
day after 2 months on D-OL-HDF.
Reduction ratio S-OL-HDF D-OL-HDF P value
Hematologic monitoringSession
Urea % 84.33 64.25 0.001 Most hematologic parameters in our study did notCreatinine % 73.12 56.73 0.001
show any significant changes (Table 4). Only the predial-Osteocalcin % 71.37 60.67 0.001
2-microglobulin % 79.84 66.311 0.05 ysis ferritin decreased from 473  263 ng/mL at baseline
Myoglobin % 65.75 56.510 0.05 to 312  147 ng/mL after 3 months (P  0.01) and toProlactin % 65.64 57.19 0.05
290 177 ng/mL after 6 months (P 0.01). Erythropoie-Weekly
Urea % 2538 38532 0.001 tin doses (3250  2052 IU/week) were not varied during
Creatinine % 2195 34015 0.001
the study and intravenous iron was increased from 24 toOsteocalcin % 21421 36339 0.001
2-microglobulin % 23911 39866 0.001 46 mg/week (sodium ferric gluconate complex) during
Myoglobin % 19714 33962 0.001 the study period.
Prolactin % 19613 34355 0.001
Nutrition and inflammation parameters
Interdialytic weight gain per session decreased from
2.17  1.5 kg to 1.25  0.5 kg, but weekly interdialytic
dium, potassium, bicarbonate, calcium, phosphorus, and weight gain rose from 7.62  1.5 kg on S-OL-HDF to
iPTH are shown in Table 3. Althought serum phosphate 8.48  2.5 kg on D-OL-HDF (P  0.001) (Table 5).
did not change, phosphate binders (calcium carbonate Mean nPCR increased from 0.93 0.2 g/kg/day on S-OL-
in seven patients and calcium acetate plus aluminium hy- HDF to 1.18  0.3 g/kg/day after 3 months (P  0.05)
droxide in one patient) were reduced from 7.3 3 tablets/ and 1.13  0.2 g/kg/day after 6 months on D-OL-HDF.
day on S-OL-HDF to 2.9  3 tablets/day after 3 months There were no significant changes in serum protein, albu-
and 2.85  4 after 6 months (P  0.001) on D-OL-HDF. min, prealbumin, transferrin, total cholesterol, HDL cho-
The mean baseline value for 2-microglobulin (29.5  lesterol, LDL cholesterol, triglycerides, fibrinogen and
2 mg/L) was 15 times higher than normal range and C-reactive protein. Body weight (measured as dry weight
myoglobin (214  75 mg/L) was three times higher than after dialysis) increased from 67.8 8 kg on S-OL-HDF
maximal normal range. The mean baseline predialysis to 68.3  8 kg after 3 months and 69.4  8 kg after 6
level of osteocalcin (18.4  19 mg/L) was slightly higher months (NS) on D-OL-HDF.
than maximal normal range, and the baseline predialysis
Blood pressure monitoringlevels of prolactin (16.4  10 ng/mL) were within the
normal range and remained constant during the 6-month During the baseline period, three patients had hyper-
tension (predialysis mean blood pressure 110 mm Hg)study period (Table 3). In the diabetic patient, the insulin
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Table 3. Change from three times a week on-line hemodiafiltration (OL-HDF) to short daily on-line hemodiafiltration (D-OL-HDF).
Predialysis levels of sodium, potassium, bicarbonate, urea, creatinine, uric acid, calcium, phosphorus, intact PTH (iPTH), osteocalcin
and prolactin
Baseline Month 1 Month 2 Month 3 Month 4 Month 5 Month 6
Sodium mmol/L 1391 1404 1404 1394 1405 1411 1394
Potassium mmol/L 5.10.5 4.50.4 4.60.7 4.70.5 4.60.7 4.70.8 4.80.5
Bicarbonate mmol/L 22.02 23.63 23.32 24.43a 23.53 25.63b 24.53a
Uric acid mg/dL 6.081 5.121b 4.731b 5.031b 4.801b 4.641b 4.711b
Urea mg/dL 10520 8318b 8317b 8324b 9110a 8215b 8715b
Creatinine mg/dL 7.381 6.191b 5.761b 6.031b 5.961b 6.231b 6.341b
Calcium mg/dL 9.80.3 9.70.7 9.60.7 9.60.6 9.60.4 9.50.5 9.80.6
Phosphorus mg/dL 4.291 4.541 4.681 4.111 4.811 4.461 4.651
iPTH pg/mL 136111 275288 176156 171157 189171 161141 11790
Osteocalcin mg/L 18.419 19.619 19.020 23.018 22.117 19.816 17.414
Prolactin ng/mL 16.410 17.311 19.414 18.912 17.812 19.813 17.012
aP  0.05. bP  0.01 with respect to baseline value (ANOVA repeated measures)
was withdrawn and only one patient had high blood
pressure. Reductions in blood pressure were observed al-
though without achieving statistical significance (Table 4).
Cardiac parameters
Six patients had LVH assessments performed while
on S-OL-HDF, just before the beginning of the study.
A considerable reduction of LVH was observed when
patients were switched to D-OL-HDF. LVM decreased
from 167 76 g at baseline to 124 47 g after 3 months
(P  0.01) and 118  37 g after 6 months (P  0.01).
LVMI decreased from 98  45 g/m2 at baseline to 72 
28 g/m2 after 3 months (P  0.01) and 69  22 g/m2 after
6 months (P  0.01). LVH was present in only one
patient at the end of the 6-month study period. A signifi-
cant reduction in IVS, AWT, PWT, LWT, and IWT was
also observed. There were no changes in in LVIDD,
LVISD, LA, AO, LVEDV, LVESV, and EF (Table 6)
Finally, predialysis homocysteine levels decreased from
21.8 3 mol/L on S-OL-HDF to 12.5 2 mol/L after
3 months (P  0.01) and 14.1  5 kg after 6 months
(P  0.01) on D-OL-HDF.
DISCUSSION
Several groups [1–8] have reported excellent clinical
results with higher frequency or daily dialysis because it
is more physiologic and decreases the fluctuations in
volume, solutes, and electrolytes. Improvement in com-
fort during and between dialysis sessions, clinical andFig. 4. Change from three times a week on-line hemodiafilitration
biochemical parameters, anemia correction, hyperten-(HDF) to short daily on-line hemodiafiltration (D-OL-HDF). (A ) Pre-
dialysis serum 2-microglobulin (11,800 D) over 6 months. (B ) Myoglo- sion control, nutrition status, and quality of life have
bin (17,200 D) levels over 6 months. P  0.01, analysis of variance been reported. OL-HDF is a safe technique that allows(ANOVA) repeated measures.
a considerable increase in convection, a high dialysis dose
for both small and large molecules, and good control of
anemia, nutrition, and blood pressure. In a previous pa-and two were receiving antihypertensive medication. Av-
per [20], we reported that OL-HDF is the best techniqueerage baseline values were systolic blood pressure 144.5
for large molecule removal. The present study is the first24 mm Hg; diastolic blood pressure 79.3  11 mm Hg;
experience reported in literature with D-OL-HDF andand mean blood pressure 101.0 15 mm Hg. During the
first month on D-OL-HDF, antihypertensive medication shows that the switch from standard three times a week
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Table 4. Change from three times a week on-line hemodiafiltration (OL-HDF) to short daily on-line hemodiafiltration (D-OL-HDF).
Hematologic parameters and blood pressure findings
Baseline Month 1 Month 2 Month 3 Month 4 Month 5 Month 6
Hemoglobin g/dL 12.31 12.71 12.51 12.81 12.61 12.81 12.81
Hematocrit % 36.85 37.85 36.95 38.24 37.23 38.04 38.14
Leucocytes 103/lL 6.911 6.911 6.932 6.331 6.831 6.852 6.141
Lymphocyte 103/lL 1.930.3 1.780.5 1.710.3 1.920.4 1.870.4 1.880.3 1.840.4
TS % 31.912 31.212 24.57 31.711 28.310 28.414 27.511
Ferritin ng/mL 473263 360152a 375160a 312147b 277151b 273165b 290177b
Iron doses mg/week 248 2714 2818 2818 3732 4333a 4631b
EPO doses IU/kg/week 48.028 47.528 47.428 47.328 47.028 46.828 46.828
ERI 4.012 3.832 3.712 3.682a 3.752 3.762 3.752
SBP mm Hg 14424 14023 13029 13125 13017 13122 13518
DBP mm Hg 79.311 78.313 71.414 70.116 72.411 75.210 75.512
MBP mm Hg 10115 98.916 90.818 90.418 91.412 93.813 95.614
Abbreviations are: TS, transferrin saturation; EPO, erythropoietin; ERI, EPO resistivity index (EPO doses/hemoglobin); SBP, systolic blood pressure; DBP,
diastolic blood pressure; MBP, mean blood pressure.
aP  0.05; bP  0.01 with to respect baseline value (ANOVA repeated measures); ciron dose was endovenous sodium ferric gluconate complex
Table 5. Change from three times a week on-line hemodiafiltration (OL-HDF) to short daily on-line hemodiafiltration (D-OL-HDF).
Nutrition and inflammation findings
Baseline Month 1 Month 2 Month 3 Month 4 Month 5 Month 6
nPCR g/kg/day 0.9310.2 1.1230.3 1.0750.3 1.1780.3a 1.1600.1a 1.0640.3 1.1290.2
Body weight kg 67.88 68.18 68.18 68.48 68.88 69.28 69.48
Weight gain kg 2.170.5 1.280.7b 1.130.4b 1.240.7b 1.260.4b 1.260.6b 1.150.6b
Total protein mg/dL 7.00.3 7.30.6 6.80.5 6.90.3 7.00.4 6.90.4 7.00.5
Albumin mg/dL 3.730.2 3.740.2 3.620.3 3.770.4 3.760.2 3.650.2 3.770.2
Prealbumin mg/dL 33.15 35.06 32.37 32.27 33.85 30.25 32.34
Transferrin mg/dL 16917 17626 16222 17915 18421 18620 19517
T cholesterol mg/dL 18644 20053 19059 20360 20566 20372 20158
HDL-c mg/dL 49.58 57.09 51.116 58.96 54.97 56.36 57.111
LDL-c mg/dL 10233 11342 10838 11552 11856 13582 12545
Triglycerides mg/dL 16564 14996 15269 14682 15792 15462 16292
Fibrinogen mg/dL 428136 44535 48677 39224 42064 34338 35352
CRP mg/L 6.77 8.412 20.936 3.84 4.97 5.410 3.44
Abbreviations are: nPCR, normalized protein catabolic rate; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol.
aP  0.05; bP  0.01 with respect to baseline value (ANOVA repeated measures)
OL-HDF to short D-OL-HDF has been satisfactory with
excellent clinical tolerance and patient acceptance. ItTable 6. Change from three times a week on-line hemodiafiltration
(OL-HDF) to short daily on-line hemodiafiltration (D-OL-HDF). should be pointed out that, during the baseline period,
Cardiac magnetic resonance imaging data
the patients received a high dialysis dose and mantained
Baseline Month 3 Month 6 a good control of anemia, nutrition, and blood pressure.
LVIDD mm 45.62 47.13 46.94 Although dialysis time was similar during both treat-
LVISD mm 29.03 29.24 28.73 ment schedules, an increase in the dialysis dose was ob-IVS mm 15.03.9 12.93.2a 12.71.8a
tained with D-OL-HDF, which confirms the beneficialAWT mm 11.94.6 8.31.7a 9.41.4a
PWT mm 11.92.2 9.92.6b 9.82.3b effect of higher frequency. Although weekly spKt/V or
LWT mm 11.52.9 9.71.7 9.52.0 weekly eKt/V were similar between both study periods,IWT mm 12.63.1 9.62.7b 10.12.1b
LA mm 34.74.2 36.55.0 37.66.0 the EKR and standard Kt/V, proposed to measure the
AO mm 33.84.0 33.82.6 33.82.8 dialysis dose in dialysis regimens with different fre-
LVEDV mL 127.918 116.418 113.413
quency, were 26% and 48% higher on D-OL-HDF, re-LVESV mL 53.39 39.712 44.711
EF % 60.75 66.410 62.38 spectively. Weekly URR also was 52% higher in the
LVM g 166.976 123.747b 118.137b daily schedule; this is a simple method that is able to show
LVMI g/m2 97.945 72.428b 68.922b
differences between regimens with different frequencies
Abbreviations are: LVIDD, left ventricular internal diameter at end-diastole;
and the weekly reduction ratio can be used for any soluteLVISD, left ventricular internal end-systole diameter; IVS, interventricular sep-
tal thickness; AWT, anterior wall thickness; PWT, posterior wall thickness; LWT, as well as urea.
lateral wall thickness; IWT, inferior wall thickness; LA, left atrium dimension;
Solute and fluid removal are the major goals of dialysis.AO, aortic root dimension; LVEDV, left ventricular end diastole volume;
LVESV, left ventricular end systole volume; EF, ejection fraction; LVM, left Reduction of elevated predialysis uremic toxins levels may
ventricular wall mass; LVMI, LVM index.
aP 0.05; bP 0.01 with respect to baseline value (ANOVA repeated measures) prevent or postpone the onset of dialysis-related complica-
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tions. The difficulty in reducing large molecule plasma tance, and metabolic acidosis could be also involved [32].
Galland et al [27] reported similar data and found thatlevels can be explained by the low distribution volume
(approximately 20% of the body weight) or by a multi- short daily hemodialysis rapidly improves nutritional sta-
tus, reporting an increase in body weight of 1.8 kg aftercompartimental model [21, 22]. In 2-microglobulin, the
best results have been reported by Raj et al [23] with 6 months without any changes in weekly Kt/V.
An improvement in phosphate control has been ob-daily 8-hour nocturnal dialysis. They noted that the pre-
dialysis 2-microglobulin levels progressively declined served in this study and it has also been reported by
most authors in daily dialysis treatment. Although wefrom 27.2 to 13.7 mg/dL by 9 months. In the present
paper, we observed a 21% reduction in predialysis did not observe significant differences from predialysis
phospate levels, this could be due to the existence ofplasma 2-microglobulin levels over a 6-month period.
Resistance to diffusion within tissues and organs cre- confounding factors such as a reduction in phosphate
binders (60% in our patients) and an increase in phos-ates solute disequilibrium gradients. The resistance to
diffusion can be quantitated as the intercompartment phate intake.
Cardiovascular disease is the most common cause ofmass-transfer coefficient (Kc) and is molecular size–
sensitive. It is known that to obtain the same TAC in mortality in chronic hemodialysis patients, being the at-
tributed cause of death in approximately 50% of thepatients treated intermittently, the dialysis dose must be
greater than during daily or continuous treatment. This cases. In this study, the change to D-OL-HDF improved
several cardiovascular risk factors such as arterial hyper-phenomenon is magnified in solutes that have a lower
Kc than urea [24, 25]. Our study supports this argument tension, hyperuricemia, LVH, and hyperhomocysteine-
mia. Hypertension is strongly associated with mortalitysince we observed an increase in solute removal with
higher frequency and this effect was more significant in and is very prevalent in dialysis patients ranging from
75% to 100%. Although our patients were relatively wellsolutes with greater molecular size or lower Kc (Fig. 3).
A decrease in erythropoietin dose has been reported controlled at baseline (only three patients were hyper-
tensive and two were receiving drugs), better blood pres-by Vos, Zilch, and Kooistra [26], Galland et al [27],
and Pierratos [28], amounting to 20%, 63%, and 40%, sure control was achieved with D-OL-HDF without anti-
hypertensive medications.respectively. Buoncristiani et al [1] initially reported an
increase in hemoglobin from 8.1  2 g/dL to 13.8  3.8 LVH is an independent cardiovascular risk factor and
is strongly associated with mortality in dialysis patientsg/dL, although the erythropoietin dose was not men-
tioned. We did not observe any changes in hemoglobin [33]. LVH is present in 70% to 80% of the dialysis popu-
lation [34]. Hypertension, poor extracelular fluid volumelevels or erythropoietin dose in this study. Compared
with these papers our patients received a higher dialysis control, anemia, and uremia (accumulation of uremic
toxins and circulatory vasoconstrictors) have been impli-dose with OL-HDF and baseline hemoglobin levels were
higher with a low erythropoietin dose (50 UI/kg/week). cated in the pathophysiology of LVH. In the present
study, we observed a marked regression of LVH. TheFerritin was significantly reduced during the study and
iron supplements were raised gradually to improve func- LVMI was reduced by 30% after 6 months, after patients
on S-OL-HDF were switched to D-OL-HDF. MRI hastional iron deficiency. The use of intravenous iron in
daily dialysis experiencies has not been clearly specified been validated for measurements of LV and RV wall
mass [35]. Because of its high accuracy and superiorin the literature but it is possible that iron needs in daily
dialysis may be higher. Kooistra et al [7] and Pierratos reproducibility, MRI may be considered the gold stan-
dard for the assessment of ventricular dimensions, func-et al [5] did not observe any changes in erythropoietin
dose and anemia control in initial reports but, in later tional parameters and left and right ventricular mass
[36]. Other authors have reported regression of cardiacpapers, reported a decrease in erythropoietin dose re-
lated to changes in iron use [26, 28]. hypertrophy measured with echocardiography. Fagugli
et al [37] and Galland et al [27] reported a LVMI reduc-An increase in body weight (1.5 kg after 6 months)
has been observed in this study as a marker of improve- tion of 18% and 31%, respectively, in patients receiving
short daily dialysis. Recently, Chan et al [38] reportedment in nutritional status. A rapid improvement in appe-
tite was reported and an increase of nPCR was observed. a LVMI reduction of 22% in 28 patients receiving slow
nocturnal daily dialysis.Improvement of certain causes of anorexia such as post-
dialysis fatigue, reduction in fluid overload, uremic milieu, Hyperhomocysteinemia has been identified as an inde-
pendent risk factor for cardiovascular disease [39]. Themedium and large-sized molecule removal was observed
with the change to D-OL-HDF. Accumulation of sub- moderate elevation of total homocysteine concentrations
in plasma, which is observed in at least 85% of hemodial-stances 5000 D isolated from uremic plasma [29] and
leptin [30, 31], 16,000 D have been related with anorexia ysis patients, can be lowered by appropriate cofactor
supplementation (folic acid, vitamin B6, and B12). How-and nutrition. Improvement in insulin resistance, growth
hormone and insulin-like growth factor-1 (IGF-1) resis- ever, administration of folic acid at pharmacologic doses,
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dialysis are the indications for ultra short daily auto dialysis. Transeither alone or combined with vitamin B6 and B12, is only ASAIO 35:503–505, 1989
partially effective in reducing plasma homocysteine and 3. Mastrangelo F, Alfonso L, Napoli M, et al: Dialysis with in-
creased frequency of sessions (Lecce dialysis). Nephrol Dial Trans-few dialysis patients normalize their homocysteine con-
plant 13(Suppl 6):139–147, 1998centrations entirely [40]. This elevation of homocysteine
4. Pinciaroli AR: Results of daily hemodialysis in Catanzaro: 12
concentrations is mainly due to the reduction of plasma years experience with 22 patients treated for more than one year.
Home Int 2:12–17, 1998homocysteine clearance, although the cause of this de-
5. Pierratos A, Ouwendyk M, Francoeur R, et al: Nocturnal hemo-crease is still unkown [41]. It is possible that the reduction
dialysis: Three-year experience. J Am Soc Nephrol 9:859–868, 1998
of clearance is due to multiple abnormalities of the re- 6. Depalma JR, Pecker EA, Maxwell MH: A new automatic coil
dialyzer system for “daily” dialysis. Proc Eur Dial Transplant Assocmethylation pathway that are not related to folate [42].
6:26–34, 1969Therefore, the inhibition by uremic toxins of enzymes
7. Kooistra MP, Vos J, Koomans HA, Vos P: Daily home haemodial-
involved in the extrarenal homocysteine removal has ysis in The Netherlands: Effects on metabolic control, haemody-
namics, and quality of life. Nephrol Dial Transpl 13:2853–2860,been suggested as an alternative explanation for the ele-
1999vated homocysteine levels in end-stage renal disease
8. Lockridge RS, Anderson HK, Coffey LT, Craft VW: Nightly
(ESRD) [43]. The effect of dialysis itself on plasma home hemodialysis in Lynchburg, Virginia: Economic and logistic
considerations. Semin Dial 12:440–447, 1999homocysteine concentration has been investigated in
9. Canaud B, Flavier JL, Argiles A, et al: Hemodiafiltration withonly a small number of studies. Interestingly, the reduc-
on-line production of substitution fluid: Long-term safety and
tion in homocysteine was not markedly different be- quantitative assessment of efficacy. Contrib Nephrol 108:12–22,
1994tween high- and low-flux devices [44]. In the present
10. Maduell F, del Pozo C, Garcia H, et al: Change from conven-study, plasma homocysteine levels decreased near nor-
tional haemodiafiltration to on-line haemodiafiltration. Nephrol
mality without any changes in medical therapy, but only Dial Transpl 14:1202–1207, 1999
11. Lornoy W, Becaus L, Billiouw JM, et al: On-line haemodiafiltra-a higher frequency of dialysis. Similar data have been
tion. Remarkable removal of 2-microglobulin. Long term observa-reported by Floridi et al [45], where homocysteine levels
tions. Nephrol Dial Transpl 15(Suppl 24):49–54, 2000
in 16 patients switched from standard hemodialysis to 12. Daugirdas JT: Second generation logarithmic estimates of single-
pool variable volume Kt/V: An analysis of error. J Am Soc Nephroldaily short hemodialysis diminished from 27.5  11
4:1205–1213, 1993mol/L to 17.2  7 mol/L.
13. Maduell F, Garcia-Valdecasas J, Garcia H, et al: Validation
of different methods to calculate Kt/V considering postdialysis
rebound. Nephrol Dial Transplant 12:1928–1933, 1997
CONCLUSION 14. Casino FG, Lopez T: The equivalent renal urea clearance: A
new parameter to assess dialysis dose. Nephrol Dial TransplantThe change from three times a week S-OL-HDF to 11:1574–1581, 1996
short D-OL-HDF has been satisfactory. The main bene- 15. Gotch FA: The current place of urea kinetic modelling with respect
to different dialysis modalities. Nephrol Dial Transplant 13(Supplfits observed in this study were the excellent clinical
6):10–14, 1998tolerance and patient acceptance, disappearance of post- 16. Lopot F, Va´lek A: Time-averaged concentration—Time-averaged
dialysis fatigue, better dialysis adequacy (EKR, Kt/Vstd, deviation: A new concept in mathematical assessment of dialysis
adequacy. Nephrol Dial Transplant 3:846–848, 1998weekly URR and TAD), a higher removal of medium and
17. Bergstro¨m J, Wehle B: No change in corrected 2-microglobulinlarge-sized molecules, a reduction of phosphate binders, concentration after cuprophane haemodialysis. Lancet 1:628–629,
an improvement in nutritional status and, finally, a marked 1987
18. Sklar A, Newman N, Scott R, et al: Identification of factorsreduction of cardiovascular risk factors: better control
responsible for postdialysis fatigue. Am J Kidney Dis 34:464–470,of blood pressure without antihypertensive medication, 1999
reduction of ferritin and uric acid levels, regression of 19. Rademakers FE, Bogaert J: Cardiac function, in Magnetic Reso-
nance of the Heart and Great Vessels, edited by Bogaert J, Duer-LVH and normalization of homocysteinemia levels.
inckx AJ, Rademakers FE, Berlin, Springer, 1999, pp 95–111
20. Maduell F, Navarro V, Cruz MC, et al: Osteocalcin and myoglo-
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